MTOR and kidney cancer: It has been found that in kidney cancer cells 786-O and SN12C, PBRM1 deficiency not only increases the levels of Akt and mTOR in the cells and their phosphorylated forms, activates AKT-mTOR signaling, but also increases the expression of mRNA and protein, which are key enzymes in glycolysis, such as phosphofructokinase (PFKP), enolase (ENO1), pyruvate kinase (PKM), and LDHA.